This is a financial update on various stocks from Benzinga. It includes the stock prices and percentage changes for multiple companies such as Aspira Women's Health Inc, Capstone Holding Corp, Coeptis Therapeutics Holdings Inc, Citius Oncology Inc, Gelteq Ltd, Intensity Therapeutics Inc, Kindly MD Inc, Know Labs Inc, OneMedNet Corp, Polyrizon Ltd, Radiopharm Theranostics Ltd, and Tenon Medical Inc. The article also offers an option to reveal the full score and rankings of any stock.

Based on the information provided, it seems that Citius Oncology Inc. has reported its financial performance for the fiscal year ending December 31, 2024. The company had a total of 71,552,402 common stocks issued and outstanding, with additional paid-in capital amounting to $87,220,249. However, it also had an accumulated deficit of $45,937,792. The total stockholders' equity amounted to $41,289,612. In terms of operating expenses, the company spent $1,264,508 on research and development, $3,321,979 on general and administrative costs, and $1,808,478 on stock-based compensation for general and administrative purposes. Comparisons with the previous year's numbers were not fully provided in this section.

1) Brief Summary: Citius Oncology, Inc. has been experiencing a significant downward trend in terms of its stock performance, with a negative Simple Moving Average (SMA) over both 50 and 200 days. The company's market capitalization is relatively small at $50.80M, and it has a high insider ownership at 95.08%, indicating that the management or individuals inside the company own most of the shares. However, the company's sales over the past five years have been stagnant, and there is no data on revenue for the most recent quarter or fiscal year. A potential concern is the relatively high debt-to-equity ratio of 0.09, which could be problematic if the company's earnings continue to underperform. The EPS (Earnings Per Share) surprise of -50.00% is also a red flag, indicating that the company's earnings were well below what analysts had predicted. 2) MARKET_SCORE: 35

: Given the negative trends and lack of revenue growth, the likelihood of an upward move in the stock price appears to be low. 3) PRICE_TARGET: $0.85

: Considering the company's current challenges and market conditions, a modest price increase of 20% from the latest close price of $0.71 seems more realistic. 4) AI_RPT_HEADLINE: "Citius Oncology's Stock Struggles Amidst Revenue Stagnation and High Debt"

-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes

====================================================== : 2025-03-24 14:35:06

# Analysis Completed Elapsed Time: 44.49 seconds